Scott A K, Rigby J W, Webster J, Hawksworth G M, Petrie J C, Lovell H G
Br Med J (Clin Res Ed). 1982 May 22;284(6328):1514-6. doi: 10.1136/bmj.284.6328.1514.
The effect of once-daily dosage of the two most widely prescribed cardioselective beta-adrenoceptor antagonists used to treat hypertension--namely, atenolol and metoprolol--was studied in nine carefully selected hypertensive outpatients. Each patient received atenolol 50 mg/day, atenolol 100 mg/day, metoprolol 100 mg/day, and metoprolol 200 mg/day in a sustained-release formulation (as Lopresor SR) according to a randomised sequence. After three weeks' treatment with each drug given once daily comparisons of the treatments 24 hours after dosing showed no important differences between 50 and 100 mg atenolol/day. Metoprolol, as both the standard and the slow-release formulations, had some limitations in controlling systolic blood pressure and heart rate. These results suggest that the recommendations for the treatment of hypertension with these cardioselective beta-adrenoceptor antagonists should be reconsidered since doses smaller than those recommended are almost as effective and much cheaper.
在9名精心挑选的高血压门诊患者中,研究了用于治疗高血压的两种最常用的心脏选择性β-肾上腺素能拮抗剂——阿替洛尔和美托洛尔——每日一次给药的效果。每位患者按照随机顺序接受阿替洛尔50毫克/天、阿替洛尔100毫克/天、美托洛尔100毫克/天以及美托洛尔200毫克/天的缓释制剂(如倍他乐克缓释片)。在每种药物每日给药一次进行三周治疗后,给药24小时后各治疗组之间的比较显示,阿替洛尔50毫克/天和100毫克/天之间没有显著差异。美托洛尔,无论是标准制剂还是缓释制剂,在控制收缩压和心率方面都有一些局限性。这些结果表明,对于使用这些心脏选择性β-肾上腺素能拮抗剂治疗高血压的建议应该重新考虑,因为比推荐剂量小的剂量几乎同样有效且成本低得多。